Novel Hydrogenated Derivatives of Chemically Modified Curcumin CMC2.24 Are Potent Inhibitors of Melanogenesis in an In Vitro Model: Influence of Degree of Hydrogenation.
CMC2.24
chemically modified curcumin
hydrogenation
melanocytes
melanogenesis
partial hydrogenation
recovery
skin lightening
tetrahydro-CMC2.24
tyrosinase
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
12 Jun 2023
12 Jun 2023
Historique:
received:
20
04
2023
revised:
29
05
2023
accepted:
08
06
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Chemically modified curcumin, CMC2.24, is a promising therapeutic that has shown efficacy in ameliorating excessive pigmentation in our previous studies. However, its inherent disadvantages of color, stability, solubility, and cytotoxicity to melanocytes and keratinocytes at concentrations > 4 µg/mL posed challenges in its use in cosmetic formulations. To overcome these limitations, chemical reduction by hydrogenation of CMC2.24 (compound
Identifiants
pubmed: 37374155
pii: life13061373
doi: 10.3390/life13061373
pmc: PMC10304319
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : ARAD Award, Center for Biotechnology, Stony Brook Foundation
ID : NA
Références
Biol Pharm Bull. 2007 Nov;30(11):2007-11
pubmed: 17978467
Food Funct. 2023 Mar 20;14(6):2822-2835
pubmed: 36866793
Biomolecules. 2021 Apr 30;11(5):
pubmed: 33946371
Cancers (Basel). 2022 Sep 24;14(19):
pubmed: 36230575
PLoS One. 2010 Apr 16;5(4):e10202
pubmed: 20419137
J Inflamm Res. 2023 Feb 23;16:779-792
pubmed: 36860795
EMBO J. 1992 Feb;11(2):519-26
pubmed: 1537333
Am J Clin Dermatol. 2011 Apr 1;12(2):87-99
pubmed: 21348540
Antibiotics (Basel). 2022 Jan 20;11(2):
pubmed: 35203738
Int J Mol Sci. 2021 Jun 03;22(11):
pubmed: 34205035
Front Oncol. 2022 Mar 14;12:842496
pubmed: 35359389
J Invest Dermatol. 1993 Feb;100(2 Suppl):209S-213S
pubmed: 8433009
J Eur Acad Dermatol Venereol. 2011 Jul;25(7):749-57
pubmed: 21054565
Drug Des Devel Ther. 2015 Sep 03;9:5051-60
pubmed: 26366056
Biol Pharm Bull. 2007 Jan;30(1):74-8
pubmed: 17202663
Dermatol Clin. 2017 Apr;35(2):219-227
pubmed: 28317530
J Inflamm Res. 2021 Oct 16;14:5337-5347
pubmed: 34703272
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2003 Dec;147(2):137-45
pubmed: 15037894
Antioxidants (Basel). 2021 Jul 15;10(7):
pubmed: 34356362
Angew Chem Int Ed Engl. 2017 Aug 7;56(33):9812-9815
pubmed: 28661582
J Exp Pharmacol. 2022 Feb 09;14:73-85
pubmed: 35173493
Heliyon. 2020 Nov 12;6(11):e05469
pubmed: 33241148
Toxics. 2020 Dec 02;8(4):
pubmed: 33276624
Eur J Pharmacol. 2015 Oct 5;764:1-8
pubmed: 26118836
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6994-7002
pubmed: 16203793
Int J Cancer. 2009 Mar 15;124(6):1470-7
pubmed: 19085934
Pigment Cell Res. 2005 Feb;18(1):2-12
pubmed: 15649147
Carcinogenesis. 1995 Oct;16(10):2493-7
pubmed: 7586157
Anal Biochem. 2003 Jul 15;318(2):260-9
pubmed: 12814630
Bioorg Med Chem. 2005 Nov 15;13(22):6175-81
pubmed: 16084726
J Invest Dermatol. 2011 Nov 17;131(E1):E8-E11
pubmed: 22094404
Curr Oncol Rep. 2018 Sep 24;20(11):87
pubmed: 30250984
J Invest Dermatol. 1979 Aug;73(2):141-3
pubmed: 88488
Int J Mol Sci. 2020 Jan 30;21(3):
pubmed: 32019241
J Asian Nat Prod Res. 2009 Nov;11(11):918-28
pubmed: 20183254
J Cosmet Dermatol. 2021 Sep;20(9):2917-2923
pubmed: 33544960
Cancer Res. 2004 Aug 1;64(15):5270-82
pubmed: 15289333
Antioxidants (Basel). 2020 Jul 18;9(7):
pubmed: 32708455
Biol Pharm Bull. 2007 Jun;30(6):1052-5
pubmed: 17541153
Chem Biodivers. 2013 Mar;10(3):313-27
pubmed: 23495149
Life Sci. 2001 Dec 7;70(3):253-67
pubmed: 12005259
J Pharm Anal. 2020 Aug;10(4):334-345
pubmed: 32923007
Pigment Cell Res. 2004 Apr;17(2):96-110
pubmed: 15016298